全文获取类型
收费全文 | 13499篇 |
免费 | 801篇 |
国内免费 | 47篇 |
专业分类
耳鼻咽喉 | 246篇 |
儿科学 | 357篇 |
妇产科学 | 253篇 |
基础医学 | 1729篇 |
口腔科学 | 871篇 |
临床医学 | 1012篇 |
内科学 | 3120篇 |
皮肤病学 | 308篇 |
神经病学 | 983篇 |
特种医学 | 312篇 |
外科学 | 2115篇 |
综合类 | 78篇 |
现状与发展 | 1篇 |
一般理论 | 7篇 |
预防医学 | 1213篇 |
眼科学 | 200篇 |
药学 | 884篇 |
中国医学 | 50篇 |
肿瘤学 | 608篇 |
出版年
2023年 | 92篇 |
2022年 | 204篇 |
2021年 | 375篇 |
2020年 | 271篇 |
2019年 | 413篇 |
2018年 | 487篇 |
2017年 | 306篇 |
2016年 | 361篇 |
2015年 | 396篇 |
2014年 | 479篇 |
2013年 | 584篇 |
2012年 | 801篇 |
2011年 | 911篇 |
2010年 | 523篇 |
2009年 | 458篇 |
2008年 | 667篇 |
2007年 | 750篇 |
2006年 | 709篇 |
2005年 | 602篇 |
2004年 | 567篇 |
2003年 | 464篇 |
2002年 | 462篇 |
2001年 | 321篇 |
2000年 | 398篇 |
1999年 | 301篇 |
1998年 | 116篇 |
1997年 | 73篇 |
1996年 | 56篇 |
1995年 | 75篇 |
1994年 | 84篇 |
1993年 | 73篇 |
1992年 | 150篇 |
1991年 | 166篇 |
1990年 | 144篇 |
1989年 | 138篇 |
1988年 | 113篇 |
1987年 | 110篇 |
1986年 | 105篇 |
1985年 | 121篇 |
1984年 | 70篇 |
1983年 | 55篇 |
1980年 | 43篇 |
1979年 | 73篇 |
1978年 | 68篇 |
1977年 | 38篇 |
1975年 | 58篇 |
1974年 | 69篇 |
1973年 | 54篇 |
1972年 | 41篇 |
1970年 | 46篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
11.
David Jiménez Castro Gema Díaz David Martí Carlos Escobar Javier Ortega Sergio García-Rull Joaquin Picher Antonio Sueiro 《Blood coagulation & fibrinolysis》2007,18(2):173-177
This study aimed to determine whether a weight-adjusted dose of subcutaneous enoxaparin is as effective and safe as oral acenocoumarol for the secondary prophylaxis of pulmonary embolism. Three hundred and eighty consecutive noncancer outpatients hospitalized with an episode of symptomatic pulmonary embolism selected treatment with acenocoumarol or enoxaparin at a dose of 1 mg/kg once daily after being informed of the type of administration and expected frequency of laboratory monitoring for both medicinal products. Endpoints were symptomatic recurrent thromboembolic events evaluated by standard objective testing, and a composite endpoint of recurrent venous thromboembolism, major bleeding, and death from any cause. One hundred and ninety-nine patients (52%) chose acenocoumarol therapy and 181 chose enoxaparin monotherapy. Four patients in the enoxaparin group (2.2%) and six patients in the acenocoumarol group (3%) had an objective thromboembolic recurrence (hazard ratio, 1.35; 95% confidence interval, 0.38-4.79; P = 0.64). Nine patients in the enoxaparin group (5.0%) had a hemorrhagic complication compared with 11 in the acenocoumarol group (5.5%) (P = 0.81). The hospital length of stay was shorter with enoxaparin compared with acenocoumarol (11 versus 16 days, P = 0.0001). Enoxaparin is as effective and safe as acenocoumarol in the secondary prevention of recurrent thromboembolic disease and is associated with shorter hospitalization. 相似文献
12.
Otavio A C Clark Gary H Lyman Aldemar A Castro Luciana G O Clark Benjamin Djulbegovic 《Journal of clinical oncology》2005,23(18):4198-4214
PURPOSE: Current treatment for febrile neutropenia (FN) includes hospitalization for evaluation, empiric broad-spectrum antibiotics, and other supportive care. Clinical trials have reported conflicting results when studying whether the colony-stimulating factors (CSFs) improve outcomes in patients with FN. This Cochrane Collaboration review was undertaken to further evaluate the safety and efficacy of the CSFs in patients with FN. METHODS: An exhaustive literature search was undertaken including major electronic databases (CANCERLIT, EMBASE, LILACS, MEDLINE, SCI, and the Cochrane Controlled Trials Register). All randomized controlled trials that compare CSFs plus antibiotics versus antibiotics alone for the treatment of established FN in adults and children were sought. A meta-analysis of the selected studies was performed. RESULTS: More than 8,000 references were screened, with 13 studies meeting eligibility criteria for inclusion. The overall mortality was not influenced significantly by the use of CSF (odds ratio [OR] = 0.68; 95% CI, 0.43 to 1.08; P = .1). A marginally significant result was obtained for the use of CSF in reducing infection-related mortality (OR = 0.51; 95% CI, 0.26 to 1.00; P = .05). Patients treated with CSFs had a shorter length of hospitalization (hazard ratio [HR] = 0.63; 95% CI, 0.49 to 0.82; P = .0006) and a shorter time to neutrophil recovery (HR = 0.32; 95% CI, 0.23 to 0.46; P < .00001). CONCLUSION: The use of the CSFs in patients with established FN caused by cancer chemotherapy reduces the amount of time spent in hospital and the neutrophil recovery period. The possible influence of the CSFs on infection-related mortality requires further investigation. 相似文献
13.
D J Castro L Hoover R B Lufkin D J Castro T S Fu 《Archives of pathology & laboratory medicine》1987,111(9):867-869
This is an unusual case presentation of a young woman with a clinical history and course simulating juvenile hyaline fibromatosis, but without hyalinization in the stroma. Because of the age of onset, the apparent familial inheritance, the nonaggressive and nonregressive tumor traits, the disease cannot be classified as multicentric fibromatosis. Therefore, we are referring to this case as multicentric fibromatosis with familial inheritance, a previously unreported entity to our knowledge. 相似文献
14.
M D Luque de Castro M Valcárcel 《Journal of pharmaceutical and biomedical analysis》1990,8(4):329-336
The different types of instruments used for monitoring pharmaceutical dissolution testing are presented. Their features and the need for automation are critically discussed. The advantages of flow injection analysis in this respect are illustrated by a variety of examples clearly showing its adaptability to the different problems posed by other automatic and non-automatic alternatives. 相似文献
15.
16.
17.
18.
Luiz H Castro Luiz K Ferreira Leandro R Teles Carmen L Jorge Paula R Arantes Carla R Ono Carla C Adda Rosa F Valerio 《Seizure》2007,16(1):50-58
PURPOSE: Hypothalamic hamartoma (HH) related epilepsy presents with gelastic seizures (GS), other seizure types and cognitive deterioration. Although seizure origin in GS has been well established, non-GS are poorly characterized. Their relationship with the HH and cognitive deterioration remains poorly understood. We analyzed seizure type, spread pattern in non-GS and their relationship with the epileptic syndrome in HH. METHODS: We documented all current seizure types in six adult patients with HH-epilepsy with video-EEG monitoring, characterized clinical-electrographic features of gelastic and non-gelastic seizures and correlated these findings with cognitive profile, as well as MRI and ictal SPECT data. RESULTS: Only four seizure types were seen: GS, complex partial (CPS), tonic seizures (TS) and secondarily generalized tonic-clonic seizures (sGTC). An individual patient presented either CPS or TS, but not both. GS progressed to CPS or TS, but not both. Ictal patterns in GS/TS and in GS/CPS overlapped, suggesting ictal spread from the HH to other cortical regions. Ictal SPECT patterns also showed GS/TS overlap. Patients with GS-CPS presented a more benign profile with preserved cognition and clinical-EEG features of temporal lobe epilepsy. Patients with GS-TS had clinical-EEG features of symptomatic generalized epilepsy, including mental deterioration. CONCLUSIONS: Video-EEG and ictal SPECT findings suggest that all seizures in HH-related epilepsy originate in the HH, with two clinical epilepsy syndromes: one resembling temporal lobe epilepsy and a more catastrophic syndrome, with features of a symptomatic generalized epilepsy. The epilepsy syndrome may be determined by HH size or by seizure spread pattern. 相似文献
19.
20.
Therapy of post-renal transplantation hyperlipidaemia: comparative study with simvastatin and fish oil 总被引:1,自引:0,他引:1
Castro R; Queiros J; Fonseca I; Pimentel J; Henriques A; Sarmento A; Guimaraes S; Pereira M 《Nephrology, dialysis, transplantation》1997,12(10):2140-2143
Background: Recipients of renal transplantation (RT)
exhibit disturbances of serum lipids and apoproteins that may contribute to
their cardiovascular morbidity and mortality. In our renal transplant
department the hypercholesterolaemia prevalence at the first and fifth year
of RT is 70.0% and 81.2%, respectively. Lipid-lowering therapy has been
utilized in many Transplant Units. The aim of our study was to evaluate
post-RT hyperlipidaemia control with simvastatin or fish oil.
Method: Forty-three RT patients (26 men and 17 women)
with persistent hypercholesterolaemia and stable graft function which were
resistant to a lipid-lowering diet (American Heart Association Step Two)
were randomized into two groups and treated for 3 months with simvastatin
(S) (10 mg/day; n=25) and fish oil (F) (6 g/day; n=18). Total cholesterol
(TC), LDL-cholesterol (LDL-C), HDL-cholesterol (HDL-C), lipoprotein a
(Lp(a)), apolipoprotein A1 (Apo A1), and apolipoprotein B (Apo B) were
monitored and at the study baseline they were similar between the two
groups. Results: No side effects were detected after 3
months of therapy. In group S, the concentrations of TC (271±46
mg% vs 228±49mg%; P <0.001), TG (180±78 vs
134±45; P<0.01), LDL-C (177& plusmn;40 vs
144±43; P <0.01) and Apo B (96±18 vs
82±16; P <0.001) were significantly reduced, and Apo A1
concentration had increased (135±24 vs 149±30; P
<0.01). In group F, the concentrations of TC (266±25 vs
240±31; P <0.001), TG (203±105 vs
156±72; P=0.02) and HDL-C (63±15 vs 53±12;
P <0.01) were significantly reduced.
Conclusion: We concluded that low-dose simvastatin and
fish oil are both effective and safe in correcting post-RT hyperlipidaemia.
Further prospective studies with larger follow-up are needed to clarify
whether this therapy has an impact on cardiovascular morbidity and
mortality in RT patients. 相似文献